

29 May 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 27 May 2022, including: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Etrasimod Results Justify Pfizer's Leap Of Faith In Arena Buyout](#)" - Scrip, 24 May, 2022.)

(Also see "[PTC Confident About Commercial Prospects For Gene Therapy Upstaza](#)" - Scrip, 20 May, 2022.)

(Also see "[Could CAR-Ts Roll Into The Community Setting?](#)" - Scrip, 25 May, 2022.)

(Also see "[Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?](#)" -

Scrip, 23 May, 2022.)

(Also see "[Russia-Ukraine War Likely To Claim Sputnik V Partners As Casualty](#)" - Scrip, 19 May, 2022.)

[Click here to explore this interactive content online](#) 